Last reviewed · How we verify
Calcipotriene and betamethasone dipropionate ointment
Calcipotriene and betamethasone dipropionate ointment is a Topical combination therapy (vitamin D analog + corticosteroid) Small molecule drug developed by Galderma R&D. It is currently FDA-approved for Plaque psoriasis, Psoriatic dermatitis. Also known as: Taclonex® Ointment, Enstilar.
This combination ointment uses calcipotriene (a vitamin D analog) to normalize skin cell differentiation and betamethasone dipropionate (a potent corticosteroid) to reduce inflammation and immune activation in psoriatic plaques.
This combination ointment uses calcipotriene (a vitamin D analog) to normalize skin cell differentiation and betamethasone dipropionate (a potent corticosteroid) to reduce inflammation and immune activation in psoriatic plaques. Used for Plaque psoriasis, Psoriatic dermatitis.
At a glance
| Generic name | Calcipotriene and betamethasone dipropionate ointment |
|---|---|
| Also known as | Taclonex® Ointment, Enstilar |
| Sponsor | Galderma R&D |
| Drug class | Topical combination therapy (vitamin D analog + corticosteroid) |
| Target | Vitamin D receptor (VDR) and glucocorticoid receptor (GR) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Calcipotriene acts as a vitamin D3 receptor agonist, promoting keratinocyte differentiation and reducing proliferation of skin cells characteristic of psoriasis. Betamethasone dipropionate is a Class I (super-potent) topical corticosteroid that suppresses local inflammatory cytokines and immune cell infiltration. The combination provides synergistic anti-inflammatory and anti-proliferative effects on psoriatic lesions.
Approved indications
- Plaque psoriasis
- Psoriatic dermatitis
Common side effects
- Skin irritation or burning at application site
- Skin atrophy (with prolonged use)
- Folliculitis
- Hypercalcemia (rare, with extensive application)
Key clinical trials
- A Study to Investigate Efficacy and Safety With LEO 90100 Compared With Daivobet® Ointment in Adult Chinese Subjects With Stable Plaque Psoriasis (PHASE3)
- A Psoriasis Plaque Test With LEO 29102 Cream and Its Combination Products (PHASE2)
- LEO 90105 Ointment in Japanese Subjects With Psoriasis (PHASE3)
- A Plaque Test Comparing the Anti-psoriatic Effect of Marketed Products for Topical Use for Psoriasis Vulgaris (PHASE2)
- Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris (PHASE2)
- Efficacy and Safety of LEO 90100 Foam in Japanese Subjects With Psoriasis Vulgaris (PHASE3)
- Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel Compared With Tacalcitol Ointment and the Gel Vehicle Alone in Patients With Psoriasis Vulgaris (PHASE3)
- LEO 80185 Gel (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Calcipotriene and betamethasone dipropionate ointment CI brief — competitive landscape report
- Calcipotriene and betamethasone dipropionate ointment updates RSS · CI watch RSS
- Galderma R&D portfolio CI
Frequently asked questions about Calcipotriene and betamethasone dipropionate ointment
What is Calcipotriene and betamethasone dipropionate ointment?
How does Calcipotriene and betamethasone dipropionate ointment work?
What is Calcipotriene and betamethasone dipropionate ointment used for?
Who makes Calcipotriene and betamethasone dipropionate ointment?
Is Calcipotriene and betamethasone dipropionate ointment also known as anything else?
What drug class is Calcipotriene and betamethasone dipropionate ointment in?
What development phase is Calcipotriene and betamethasone dipropionate ointment in?
What are the side effects of Calcipotriene and betamethasone dipropionate ointment?
What does Calcipotriene and betamethasone dipropionate ointment target?
Related
- Drug class: All Topical combination therapy (vitamin D analog + corticosteroid) drugs
- Target: All drugs targeting Vitamin D receptor (VDR) and glucocorticoid receptor (GR)
- Manufacturer: Galderma R&D — full pipeline
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for Plaque psoriasis
- Indication: Drugs for Psoriatic dermatitis
- Also known as: Taclonex® Ointment, Enstilar
- Compare: Calcipotriene and betamethasone dipropionate ointment vs similar drugs
- Pricing: Calcipotriene and betamethasone dipropionate ointment cost, discount & access